Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_151_библиотеки_им_акад_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

15.09.2026

Размер:

10 Мб

Скачать

☆

<<< < Предыдущая 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 3738 / 4138 39 40 41 > Следующая >>>

Current Clinical Landscape of Immunotherapeutic Approaches in... 369

https://t.me/med1917

mutation. Lancet (London, England) 346:1399–1400. https://doi.org/10.1016/s0140-6736(95)

92408-6

Gjertsen MK, Buanes T, Rosseland AR et al (2001) Intradermal ras peptide vaccination with

granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological

responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441–450. https://doi.

org/10.1002/ijc.1205

Gnerlich JL, Mitchem JB, Weir JS et al (2010) Induction of Th17 cells in the tumor microenviron-

ment improves survival in a murine model of pancreatic cancer. J Immunol 185:4063–4071.

https://doi.org/10.4049/jimmunol.0902609

Gong Y, Zhou Q, Liao Y et al (2017) Optimized construction of MUC1-VNTRn DNA vaccine and

its anti-pancreatic cancer efﬁcacy. Oncol Lett 13:2198–2206. https://doi.org/10.3892/ol.2017.

5717

Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5:

953–964. https://doi.org/10.1038/nri1733 Gottfried E, Kunz-Schughart LA, Ebner S et al (2006) Tumor-derived lactic acid modulates

dendritic cell activation and antigen expression. Blood 107:2013–2021. https://doi.org/10.

1182/blood-2005-05-1795

Grauel AL, Nguyen B, Ruddy D et al (2020) TGFβ-blockade uncovers stromal plasticity in tumors

by revealing the existence of a subset of interferon-licensed ﬁbroblasts. Nat Commun 11:6315.

https://doi.org/10.1038/s41467-020-19920-5

Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:

515–548. https://doi.org/10.1146/annurev.immunol.23.021704.115611 Griesmann H, Drexel C, Milosevic N et al (2017) Pharmacological macrophage inhibition

decreases metastasis formation in a genetic model of pancreatic cancer. Gut 66:1278–1285.

https://doi.org/10.1136/gutjnl-2015-310049

Guerra N, Tan YX, Joncker NT et al (2008) NKG2D-deﬁcient mice are defective in tumor

surveillance in models of spontaneous malignancy. Immunity 28:571–580. https://doi.org/10.

1016/j.immuni.2008.02.016

Gulhati P, Schalck A, Jiang S et al (2023) Targeting T cell checkpoints 41BB and LAG3 and

myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic

cancer. Nat Cancer 4:62–80. https://doi.org/10.1038/s43018-022-00500-z Gunderson AJ, Kaneda MM, Tsujikawa T et al (2016) Bruton tyrosine kinase–dependent immune

cell cross-talk drives pancreas cancer. Cancer Discov 6:270–285. https://doi.org/10.1158/

2159-8290.CD-15-0827

Günes C, Rudolph KL (2013) The role of telomeres in stem cells and cancer. Cell 152:390–393.

https://doi.org/10.1016/j.cell.2013.01.010

Guo C, Chen S, Liu W et al (2019) Chapter Four – immunometabolism: a new target for improving

cancer immunotherapy. In: Wang X-Y, Fisher PBBT-A, CR (eds) Immunotherapy of cancer.

Academic Press, London, pp 195–253 Haas AR, Tanyi JL, O’Hara MH et al (2019) Phase I study of Lentiviral-transduced chimeric

antigen receptor-modiﬁed T cells recognizing Mesothelin in advanced solid cancers. Mol Ther

27:1919–1929. https://doi.org/10.1016/j.ymthe.2019.07.015 Hall M, Liu H, Malafa M et al (2016) Expansion of tumor-inﬁltrating lymphocytes (TIL) from

human pancreatic tumors. J Immunother Cancer 4:61. https://doi.org/10.1186/s40425-016-

0164-7

Hamada S, Masamune A, Shimosegawa T (2014) Inﬂammation and pancreatic cancer: disease

promoter and new therapeutic target. J Gastroenterol 49:605–617. https://doi.org/10.1007/

s00535-013-0915-x

Hardacre JM, Mulcahy M, Small W et al (2013) Addition of algenpantucel-L immunotherapy to

standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg 17:91–94.

https://doi.org/10.1007/s11605-012-2064-6

Hay JG (2005) The potential impact of hypoxia on the success of oncolytic virotherapy. Curr Opin

Mol Ther 7:353–358

370 P. Farhangnia et al.

https://t.me/med1917

He S, Fei M, Wu Y et al (2011) Distribution and clinical signiﬁcance of Th17 cells in the tumor

microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 12:

7424–7437. https://doi.org/10.3390/ijms12117424 Hecht JR, Bedford R, Abbruzzese JL et al (2003) A phase I/II trial of intratumoral endoscopic

ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic

carcinoma. Clin Cancer Res 9:555–561 Hegde S, Krisnawan VE, Herzog BH et al (2020) Dendritic cell paucity leads to dysfunctional

immune surveillance in pancreatic cancer. Cancer Cell 37:289–307.e9. https://doi.org/10.1016/

j.ccell.2020.02.008

Heise C, Sampson-Johannes A, Williams A et al (1997) ONYX-015, an E1B gene-attenuated

adenovirus, causes tumor-speciﬁc cytolysis and antitumoral efﬁcacy that can be augmented by

standard chemotherapeutic agents. Nat Med 3:639–645. https://doi.org/10.1038/nm0697-639 Herber DL, Cao W, Nefedova Y et al (2010) Lipid accumulation and dendritic cell dysfunction in

cancer. Nat Med 16:880–886. https://doi.org/10.1038/nm.2172 Hewitt DB, Nissen N, Hatoum H et al (2022) A phase 3 randomized clinical trial of chemotherapy

with or without Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with

borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg 275.

https://doi.org/10.1097/SLA.0000000000004669

Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617. https://doi.org/10.1056/

NEJMra0901557

Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells

increases during the progression of pancreatic ductal adenocarcinoma and its premalignant

lesions. Clin cancer Res 12:5423–5434. https://doi.org/10.1158/1078-0432.CCR-06-0369 Hirooka Y, Kasuya H, Ishikawa T et al (2018) A phase I clinical trial of EUS-guided intratumoral

injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC

Cancer 18:596. https://doi.org/10.1186/s12885-018-4453-z Ho WJ, Jaffee EM, Zheng L (2020) The tumour microenvironment in pancreatic cancer – clinical

challenges and opportunities. Nat Rev Clin Oncol 17:527–540. https://doi.org/10.1038/s41571-

020-0363-5

Hosein AN, Dougan SK, Aguirre AJ, Maitra A (2022) Translational advances in pancreatic ductal

adenocarcinoma therapy. Nat Cancer 3:272–286. https://doi.org/10.1038/s43018-022-00349-2 Hou Z, Pan Y, Fei Q et al (2021) Prognostic signiﬁcance and therapeutic potential of the immune

checkpoint VISTA in pancreatic cancer. J Cancer Res Clin Oncol 147:517–531. https://doi.org/

10.1007/s00432-020-03463-9

Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new

nomenclature and classiﬁcation system for pancreatic duct lesions. Am J Surg Pathol 25:

579–586 Hu G, Li G, Wen W et al (2022) Case report: B7-H3 CAR-T therapy partially controls tumor

growth in a basal cell carcinoma patient. Front Oncol 12. https://doi.org/10.3389/fonc.2022.

956593

Hu H, Hang J-J, Han T et al (2016) The M2 phenotype of tumor-associated macrophages in the

stroma confers a poor prognosis in pancreatic cancer. Tumour Biol 37:8657–8664. https://doi.

org/10.1007/s13277-015-4741-z

Huang B, Pan P-Y, Li Q et al (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the

development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

Cancer Res 66:1123–1131. https://doi.org/10.1158/0008-5472.CAN-05-1299 Huang H, Zhang Y, Gallegos V et al (2019) Targeting TGFβR2-mutant tumors exposes

vulnerabilities to stromal TGFβ blockade in pancreatic cancer. EMBO Mol Med 11:e10515.

https://doi.org/10.15252/emmm.201910515

Huang Y-H, Zhu C, Kondo Y et al (2015) CEACAM1 regulates TIM-3-mediated tolerance and

exhaustion. Nature 517:386–390. https://doi.org/10.1038/nature13848 Huber M, Brehm CU, Gress TM et al (2020) The immune microenvironment in pancreatic cancer.

Int J Mol Sci 21. https://doi.org/10.3390/ijms21197307

Current Clinical Landscape of Immunotherapeutic Approaches in... 371

https://t.me/med1917

Husain Z, Huang Y, Seth P, Sukhatme VP (2013) Tumor-derived lactate modiﬁes antitumor

immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol 191:

1486–1495. https://doi.org/10.4049/jimmunol.1202702 Imai K, Matsuyama S, Miyake S et al (2000) Natural cytotoxic activity of peripheral-blood

lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet

(London, England) 356:1795–1799. https://doi.org/10.1016/S0140-6736(00)03231-1 Ino Y, Yamazaki-Itoh R, Shimada K et al (2013) Immune cell inﬁltration as an indicator of the

immune microenvironment of pancreatic cancer. Br J Cancer 108:914–923. https://doi.org/10.

1038/bjc.2013.32

Jang J-E, Hajdu CH, Liot C et al (2017) Crosstalk between regulatory T cells and tumor-associated

dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep 20:558–571. https://

doi.org/10.1016/j.celrep.2017.06.062

Jin L, Kim HS, Shi J (2021) Neutrophil in the pancreatic tumor microenvironment. Biomolecules

11. https://doi.org/10.3390/biom11081170

Jing W, McAllister D, Vonderhaar EP et al (2019) STING agonist inﬂames the pancreatic cancer

immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer

7:115. https://doi.org/10.1186/s40425-019-0573-5 Kalbasi A, Komar C, Tooker GM et al (2017) Tumor-derived CCL2 mediates resistance to

radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res 23:137–148. https://doi.

org/10.1158/1078-0432.CCR-16-0870

Kameshima H, Tsuruma T, Kutomi G et al (2013) Immunotherapeutic beneﬁtofα-interferon

(IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.

Cancer Sci 104:124–129. https://doi.org/10.1111/cas.12046 Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy

drugs. Nat Rev Drug Discov 14:642–662. https://doi.org/10.1038/nrd4663 Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and

immunity. Annu Rev Immunol 26:677– 704. https://doi.org/10.1146/annurev.immunol.26.

021607.090331

Khaled YS, Wright K, Melcher A, Jayne D (2015) Anti-cancer effects of oncolytic viral therapy

combined with photodynamic therapy in human pancreatic cancer cell lines. Lancet 385:S56.

https://doi.org/10.1016/S0140-6736(15)60371-3

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment:

immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:

273–290. https://doi.org/10.1038/nrclinonc.2016.25 Kim DK, Jeong J, Lee DS et al (2022) PD-L1-directed PlGF/VEGF blockade synergizes with

chemotherapy by targeting CD141+ cancer-associated ﬁbroblasts in pancreatic cancer. Nat

Commun 13:6292. https://doi.org/10.1038/s41467-022-33991-6 Kim H, Seo E-H, Lee S-H, Kim B-J (2016) The telomerase-derived anticancer peptide vaccine

GV1001 as an extracellular heat shock protein-mediated cell-penetrating peptide. Int J Mol Sci

17. https://doi.org/10.3390/ijms17122054

Kimura Y, Tsukada J, Tomoda T et al (2012) Clinical and immunologic evaluation of dendritic cell-

based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced

pancreatic carcinoma. Pancreas 41:195–205. https://doi.org/10.1097/MPA.0b013e31822398c6 Kleeff J, Beckhove P, Esposito I et al (2007) Pancreatic cancer microenvironment. Int J Cancer 121:

699–705. https://doi.org/10.1002/ijc.22871 Kleeff J, Korc M, Apte M et al (2016) Pancreatic cancer. Nat Rev Dis Prim 2:16022. https://doi.org/

10.1038/nrdp.2016.22

Ko AH, Jordan AC, Tooker E et al (2020) Dual targeting of mesothelin and CD19 with chimeric

antigen receptor-modiﬁed T cells in patients with metastatic pancreatic cancer. Mol Ther 28:

2367–2378. https://doi.org/10.1016/j.ymthe.2020.07.017 Kocher HM, Basu B, Froeling FEM et al (2020) Phase I clinical trial repurposing all-trans retinoic

acid as a stromal targeting agent for pancreatic cancer. Nat Commun 11:4841. https://doi.org/10.

1038/s41467-020-18636-w

372 P. Farhangnia et al.

https://t.me/med1917

Koikawa K, Kibe S, Suizu F et al (2021) Targeting Pin1 renders pancreatic cancer eradicable by

synergizing with immunochemotherapy. Cell 184:4753–4771.e27. https://doi.org/10.1016/j.

cell.2021.07.020

Korman AJ, Garrett-Thomson SC, Lonberg N (2022) The foundations of immune checkpoint

blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 21:509–528. https://

doi.org/10.1038/s41573-021-00345-8

Laskowski TJ, Biederstädt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell

immunotherapy. Nat Rev Cancer 22:557–575. https://doi.org/10.1038/s41568-022-00491-0 Le DT, Wang-Gillam A, Picozzi V et al (2015) Safety and survival with GVAX pancreas prime and

Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pan-

creatic cancer. J Clin Oncol 33:1325–1333. https://doi.org/10.1200/JCO.2014.57.4244 Lee HH, Kim I, Kim UK et al (2022) Therapeutic efﬁacy of T cells expressing chimeric antigen

receptor derived from a mesothelin-speciﬁc scFv in orthotopic human pancreatic cancer animal

models. Neoplasia 24:98–108. https://doi.org/10.1016/j.neo.2021.12.005 Leidner R, Sanjuan Silva N, Huang H et al (2022) Neoantigen T-cell receptor gene therapy in

pancreatic cancer. N Engl J Med 386:2112–2119. https://doi.org/10.1056/NEJMoa2119662 Leung L, Radulovich N, Zhu C-Q et al (2012) Lipocalin2 promotes invasion, tumorigenicity and

gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One 7:e46677. https://doi.

org/10.1371/journal.pone.0046677

Li J, Byrne KT, Yan F et al (2018) Tumor cell-intrinsic factors underlie heterogeneity of immune

cell inﬁltration and response to immunotherapy. Immunity 49:178–193.e7. https://doi.org/10.

1016/j.immuni.2018.06.006

Li J, Gu M, Pan K et al (2012) Autologous cytokine-induced killer cell transfusion in combination

with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carci-

noma. J Immunother 35:189–195. https://doi.org/10.1097/CJI.0b013e318241d9de Li X, Gulati M, Larson AC et al (2022) Immune checkpoint blockade in pancreatic cancer: trudging

through the immune desert. Semin Cancer Biol 86:14–27. https://doi.org/10.1016/j.semcancer.

2022.08.009

Li X, Ni R, Chen J et al (2011) The presence of IGHG1 in human pancreatic carcinomas is

associated with immune evasion mechanisms. Pancreas 40:753–761 Lim SA, Kim J, Jeon S et al (2019) Defective localization with impaired tumor cytotoxicity

contributes to the immune escape of NK cells in pancreatic cancer patients. Front Immunol

10. https://doi.org/10.3389/ﬁmmu.2019.00496

Lin JH, Huffman AP, Wattenberg MM et al (2020) Type 1 conventional dendritic cells are

systemically dysregulated early in pancreatic carcinogenesis. J Exp Med 217. https://doi.org/

10.1084/jem.20190673

Liou G-Y, Döppler H, Necela B et al (2015) Mutant KRAS-induced expression of ICAM-1 in

pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancer-

ous lesions. Cancer Discov 5:52–63. https://doi.org/10.1158/2159-8290.CD-14-0474 Liu C, Yu S, Kappes J et al (2007) Expansion of spleen myeloid suppressor cells represses NK cell

cytotoxicity in tumor-bearing host. Blood 109:4336–4342. https://doi.org/10.1182/blood-2006-

09-046201

Liu J, Wang Y, Mu C et al (2022) Pancreatic tumor eradication via selective Pin1 inhibition in

cancer-associated ﬁbroblasts and T lymphocytes engagement. Nat Commun 13:4308. https://

doi.org/10.1038/s41467-022-31928-7

Liu J, Yang S, Cao B et al (2021) Targeting B7-H3 via chimeric antigen receptor T cells and

bispeciﬁc killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol

Oncol 14:21. https://doi.org/10.1186/s13045-020-01024-8 Liu M, O’Connor RS, Trefely S et al (2019) Metabolic rewiring of macrophages by CpG potentiates

clearance of cancer cells and overcomes tumor-expressed CD47

signal. Nat Immunol 20:265–275. https://doi.org/10.1038/s41590-018-0292-y

-mediated ‘don’t-eat-me’

Current Clinical Landscape of Immunotherapeutic Approaches in... 373

https://t.me/med1917

Liu Y, Guo Y, Wu Z et al (2020) Anti-EGFR chimeric antigen receptor-modiﬁed T cells in

metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22:573–580. https://doi.

org/10.1016/j.jcyt.2020.04.088

Liyanage UK, Moore TT, Joo H-G et al (2002) Prevalence of regulatory T cells is increased in

peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarci-

noma1. J Immunol 169:2756–2761. https://doi.org/10.4049/jimmunol.169.5.2756 Loncle C, Bonjoch L, Folch-Puy E et al (2015) IL17 functions through the novel REG3β–JAK2–

STAT3 inﬂammatory pathway to promote the transition from chronic pancreatitis to pancreatic

cancer. Cancer Res 75:4852–4862. https://doi.org/10.1158/0008-5472.CAN-15-0896 Long KB, Gladney WL, Tooker GM et al (2016) IFNγ and CCL2 cooperate to redirect tumor-

inﬁltrating monocytes to degrade ﬁbrosis and enhance chemotherapy efﬁcacy in pancreatic

carcinoma. Cancer Discov 6:400–413. https://doi.org/10.1158/2159-8290.CD-15-1032 López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L (2017) Control of metastasis by NK cells. Cancer

Cell 32:135–154. https://doi.org/10.1016/j.ccell.2017.06.009 Lou E (2003) Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncol 42:

660–671. https://doi.org/10.1080/0284186031000518 Lutz E, Yeo CJ, Lillemoe KD et al (2011) A lethally irradiated allogeneic granulocyte-macrophage

colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II

trial of safety, efﬁcacy, and immune activation. Ann Surg 253:328–335. https://doi.org/10.1097/

SLA.0b013e3181fd271c

Lutz V, Hellmund VM, Picard FSR et al (2023) IL18 receptor signaling regulates tumor-reactive

CD8+ T-cell exhaustion via activation of the IL2/STAT5/mTOR pathway in a pancreatic cancer

model. Cancer Immunol Res:OF1–OF14. https://doi.org/10.1158/2326-6066.CIR-22-0398 Lytle NK, Ferguson LP, Rajbhandari N et al (2019) A multiscale map of the stem cell state in

pancreatic adenocarcinoma. Cell 177:572–586.e22. https://doi.org/10.1016/j.cell.2019.03.010 Maki RG, Livingston PO, Lewis JJ et al (2007) A phase I pilot study of autologous heat shock

protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 52:

1964–1972. https://doi.org/10.1007/s10620-006-9205-2 Malmberg K-J, Carlsten M, Björklund A et al (2017) Natural killer cell-mediated

immunosurveillance of human cancer. Semin Immunol 31:20–29. https://doi.org/10.1016/j.

smim.2017.08.002

Mandili G, Curcio C, Bulfamante S et al (2020) In pancreatic cancer, chemotherapy increases

antitumor responses to tumor-associated antigens and potentiates DNA vaccination.

J Immunother Cancer 8:e001071. https://doi.org/10.1136/jitc-2020-001071 Mantovani A, Allavena P, Marchesi F, Garlanda C (2022) Macrophages as tools and targets in

cancer therapy. Nat Rev Drug Discov 21:799–820. https://doi.org/10.1038/s41573-022-

00520-5

Mantovani A, Marchesi F, Malesci A et al (2017) Tumour-associated macrophages as treatment

targets in oncology. Nat Rev Clin Oncol 14:399–416. https://doi.org/10.1038/nrclinonc.

2016.217

Mariathasan S, Turley SJ, Nickles D et al (2018) TGFβ attenuates tumour response to PD-L1

blockade by contributing to exclusion of T cells. Nature 554:544–548. https://doi.org/10.1038/

nature25501

Markowitz J, Brooks TR, Duggan MC et al (2015) Patients with pancreatic adenocarcinoma exhibit

elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer

Immunol Immunother 64:149–159. https://doi.org/10.1007/s00262-014-1618-8 McAllister F, Bailey JM, Alsina J et al (2014) Oncogenic Kras activates a hematopoietic-to-

epithelial IL-17 signaling axis in Preinvasive pancreatic neoplasia. Cancer Cell 25:621–637.

https://doi.org/10.1016/j.ccr.2014.03.014

McAuliffe PF, Jarnagin WR, Johnson P et al (2000) Effective treatment of pancreatic tumors with

two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 4:580–588. https://doi.

org/10.1016/s1091-255x(00)80106-7

374 P. Farhangnia et al.

https://t.me/med1917

McCormick KA, Coveler AL, Rossi GR et al (2016) Pancreatic cancer: update on immunotherapies

and algenpantucel-L. Hum Vaccin Immunother 12:563–575. https://doi.org/10.1080/21645515.

2015.1093264

Melief CJM (2022) T-Cell immunotherapy against mutant KRAS for pancreatic cancer. N Engl J

Med 386:2143–2144. https://doi.org/10.1056/NEJMe2204283 Meng Y, Yu Z, Wu Y et al (2017) Cell-based immunotherapy with cytokine-induced killer (CIK)

cells: From preparation and testing to clinical application. Hum Vaccin Immunother 13:1–9.

https://doi.org/10.1080/21645515.2017.1285987

Middleton G, Silcocks P, Cox T et al (2014) Gemcitabine and capecitabine with or without

telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic

cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 15:829–840. https://

doi.org/10.1016/S1470-2045(14)70236-0

Mitchem JB, Brennan DJ, Knolhoff BL et al (2013) Targeting tumor-inﬁltrating macrophages

decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic

responses. Cancer Res 73:1128–1141. https://doi.org/10.1158/0008-5472.CAN-12-2731 Miyazawa M, Ohsawa R, Tsunoda T et al (2010) Phase I clinical trial using peptide vaccine for

human vascular endothelial growth factor receptor 2 in combination with gemcitabine for

patients with advanced pancreatic cancer. Cancer Sci 101:433–439. https://doi.org/10.1111/j.

1349-7006.2009.01416.x

Mocellin S, Pooley KA, Nitti D (2013) Telomerase and the search for the end of cancer. Trends Mol

Med 19:125–133. https://doi.org/10.1016/j.molmed.2012.11.006 Morotti M, Albukhari A, Alsaadi A et al (2021) Promises and challenges of adoptive T-cell

therapies for solid tumours. Br J Cancer 124:1759–1776. https://doi.org/10.1038/s41416-021-

01353-6

Morrison AH, Diamond MS, Hay CA et al (2020) Sufﬁciency of CD40 activation and immune

checkpoint blockade for T cell priming and tumor immunity. Proc Natl Acad Sci 117:

8022–8031. https://doi.org/10.1073/pnas.1918971117 Morse MA, Nair SK, Boczkowski D et al (2002) The feasibility and safety of immunotherapy with

dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resec-

tion of pancreatic cancer. Int J Gastrointest Cancer 32:1–6. https://doi.org/10.1385/IJGC:32:1:1 Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal

precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140–2143 Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev

Immunol 8:958–969. https://doi.org/10.1038/nri2448 Mucciolo G, Curcio C, Roux C et al (2021) IL17A critically shapes the transcriptional program of

ﬁbroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad

Sci 118:e2020395118. https://doi.org/10.1073/pnas.2020395118 Mulvihill S, Warren R, Venook A et al (2001) Safety and feasibility of injection with an

E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary

carcinomas of the pancreas: a phase I trial. Gene Ther 8:308–315. https://doi.org/10.1038/sj.

gt.3301398

Murakami S, Shahbazian D, Surana R et al (2017) Yes-associated protein mediates immune

reprogramming in pancreatic ductal adenocarcinoma. Oncogene 36:1232–1244. https://doi.

org/10.1038/onc.2016.288

Murphy JE, Wo JY, Ryan DP et al (2019) Total neoadjuvant therapy with FOLFIRINOX in

combination with losartan followed by chemoradiotherapy for locally advanced pancreatic

cancer: a phase 2 clinical trial. JAMA Oncol 5:1020–1027. https://doi.org/10.1001/jamaoncol.

2019.0892

Muscarella P, Bekaii-Saab T, McIntyre K et al (2021) A phase 2 randomized placebo-controlled

adjuvant trial of GI-4000, a recombinant yeast expressing mutated RAS proteins in patients with

resected pancreas cancer. J Pancreat Cancer 7:8–19. https://doi.org/10.1089/pancan.2020.0021 Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev

Clin Oncol 18:85–100. https://doi.org/10.1038/s41571-020-0426-7

Current Clinical Landscape of Immunotherapeutic Approaches in... 375

https://t.me/med1917

Nakayama C, Tanoue K, Idichi T et al (2022) Implications of PD-1, Tim-3, and TIGIT expression

for cancer immunity and pancreatic cancer prognosis. Anticancer Res 42:3373 LP – 3380.

10.21873/anticanres.15824

Nath S, Daneshvar K, Roy LD et al (2013) MUC1 induces drug resistance in pancreatic cancer cells

via upregulation of multidrug resistance genes. Oncogenesis 2:e51– e51. https://doi.org/10.

1038/oncsis.2013.16

Ni L, Dong C (2017) New checkpoints in cancer immunotherapy. Immunol Rev 276:52–65. https://

doi.org/10.1111/imr.12524

Niethammer AG, Lubenau H, Mikus G et al (2012) Double-blind, placebo-controlled ﬁrst in human

study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-

receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 12:

361. https://doi.org/10.1186/1471-2407-12-361

Nisar M, Paracha RZ, Adil S et al (2022) An extensive review on preclinical and clinical trials of

oncolytic viruses therapy for pancreatic cancer. Front Oncol 12. https://doi.org/10.3389/fonc.

2022.875188

Noel M, O’ Reilly EM, Wolpin BM et al (2020) Phase 1b study of a small molecule antagonist of

human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/

gemcitabine in ﬁrst-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New

Drugs 38:800–811. https://doi.org/10.1007/s10637-019-00830-3 Nywening TM, Belt BA, Cullinan DR et al (2018) Targeting both tumour-associated CXCR2+

neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemothera-

peutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112–1123. https://doi.org/10.

1136/gutjnl-2017-313738

Nywening TM, Wang-Gillam A, Sanford DE et al (2016) Targeting tumour-associated

macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with border-

line resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-ﬁnding,

non-randomised, phase 1b trial. Lancet Oncol 17:651–662. https://doi.org/10.1016/S1470-2045

(16)00078-4

O’Hara MH, O’Reilly EM, Varadhachary G et al (2021) CD40 agonistic monoclonal antibody

APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of

metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol

22:118–131. https://doi.org/10.1016/S1470-2045(20)30532-5 Ochi A, Nguyen AH, Bedrosian AS et al (2012) MyD88 inhibition ampliﬁes dendritic cell capacity

to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209:1671–1687. https://doi.org/

10.1084/jem.20111706

Orhan A, Vogelsang RP, Andersen MB et al (2020) The prognostic value of tumour-inﬁltrating

lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer 132:

71–84. https://doi.org/10.1016/j.ejca.2020.03.013 Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-

derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced

immune suppression. Semin Cancer Biol 22:275–281. https://doi.org/10.1016/j.semcancer.

2012.01.011

Pagliano O, Morrison RM, Chauvin J-M et al (2022) Tim-3 mediates T cell trogocytosis to limit

antitumor immunity. J Clin Invest 132. https://doi.org/10.1172/JCI152864 Pan K, Guan X-X, Li Y-Q et al (2014) Clinical activity of adjuvant cytokine-induced killer cell

immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res

20:3003–3011. https://doi.org/10.1158/1078-0432.CCR-14-0082 Peng H, Li L, Zuo C et al (2022) Combination TIGIT/PD-1 blockade enhances the efﬁcacy of

neoantigen vaccines in a model of pancreatic cancer. Front Immunol 13. https://doi.org/10.

3389/ﬁmmu.2022.1039226

Peng P-J, Li Y, Sun S (2017) On the signi

Biol Sci 24:1754–1757. https://doi.org/10.1016/j.sjbs.2017.11.006

ﬁcance of Tim-3 expression in pancreatic cancer. Saudi J

376 P. Farhangnia et al.

https://t.me/med1917

Peng X, He Y, Huang J et al (2021) Metabolism of dendritic cells in tumor microenvironment: for

immunotherapy. Front Immunol 12. https://doi.org/10.3389/ﬁmmu.2021.613492 Peng Y-P, Xi C-H, Zhu Y et al (2016) Altered expression of CD226 and CD96 on natural killer cells

in patients with pancreatic cancer. Oncotarget 7:66586–66594. https://doi.org/10.18632/

oncotarget.11953

Peng Y-P, Zhang J-J, Liang W et al (2014) Elevation of MMP-9 and IDO induced by pancreatic

cancer cells mediates natural killer cell dysfunction. BMC Cancer 14:738. https://doi.org/10.

1186/1471-2407-14-738

Pihlak R, Weaver JMJ, Valle JW, McNamara MG (2018) Advances in molecular proﬁling and

categorisation of pancreatic adenocarcinoma and the implications for therapy. Cancers (Basel)

10. https://doi.org/10.3390/cancers10010017

Pinton L, Solito S, Damuzzo V et al (2016) Activated T cells sustain myeloid-derived suppressor

cell-mediated immune suppression. Oncotarget 7:1168–1184. https :// doi.o rg/ 10.18 632/

oncotarget.6662

Piro G, Simionato F, Carbone C et al (2017) A circulating T(H)2 cytokines proﬁle predicts survival

in patients with resectable pancreatic adenocarcinoma. Oncoimmunology 6:e1322242. https://

doi.org/10.1080/2162402X.2017.1322242

Pol J, Kroemer G, Galluzzi L (2016) First oncolytic virus approved for melanoma immunotherapy.

Oncoimmunology 5:e1115641. https://doi.org/10.1080/2162402X.2015.1115641 Posey AD Jr, Schwab RD, Boesteanu AC et al (2016) Engineered CAR T cells targeting the cancer-

associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity

44:1444–1454. https://doi.org/10.1016/j.immuni.2016.05.014 Prager I, Watzl C (2019) Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc

Biol 105:1319–1329. https://doi.org/10.1002/JLB.MR0718-269R Pylayeva-Gupta Y, Lee KE, Hajdu CH et al (2012) Oncogenic Kras-induced GM-CSF production

promotes the development of pancreatic neoplasia. Cancer Cell 21:836–847. https://doi.org/10.

1016/j.ccr.2012.04.024

Raj D, Nikolaidi M, Garces I et al (2021) CEACAM7 is an effective target for CAR T-cell therapy

of pancreatic ductal adenocarcinoma. Clin Cancer Res 27:1538–1552. https://doi.org/10.1158/

1078-0432.CCR-19-2163

Raj D, Yang M-H, Rodgers D et al (2019) Switchable CAR-T cells mediate remission in metastatic

pancreatic ductal adenocarcinoma. Gut 68:1052–1064. https://doi.org/10.1136/gutjnl-

2018-316595

Raskov H, Orhan A, Christensen JP, Gögenur I (2021) Cytotoxic CD8+ T cells in cancer and cancer

immunotherapy. Br J Cancer 124:359–367. https://doi.org/10.1038/s41416-020-01048-4 Riquelme E, Maitra A, McAllister F (2018) Immunotherapy for pancreatic cancer: more than just a

gut feeling. Cancer Discov 8:386–388. https://doi.org/10.1158/2159-8290.CD-18-0123 Roehle K, Qiang L, Ventre KS et al (2021) cIAP1/2 antagonism eliminates MHC class I–negative

tumors through T cell–dependent reprogramming of mononuclear phagocytes. Sci Transl Med

13:eabf5058. https://doi.org/10.1126/scitranslmed.abf5058 Rong Y, Qin X, Jin D et al (2012) A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the

treatment of advanced pancreatic cancer. Clin Exp Med 12:173–180. https://doi.org/10.1007/

s10238-011-0159-0

Rosenberg SA, Restifo NP, Yang JC et al (2008) Adoptive cell transfer: a clinical path to effective

cancer immunotherapy. Nat Rev Cancer 8:299–308. https://doi.org/10.1038/nrc2355 Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated

patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:

4550–4557. https://doi.org/10.1158/1078-0432.CCR-11-0116 Rusakiewicz S, Semeraro M, Sarabi M et al (2013) Immune inﬁltrates are prognostic factors in

localized gastrointestinal stromal tumors. Cancer Res 73:3499–3510. https://doi.org/10.1158/

0008-5472.CAN-13-0371

Current Clinical Landscape of Immunotherapeutic Approaches in... 377

https://t.me/med1917

Sanford DE, Belt BA, Panni RZ et al (2013) Inﬂammatory monocyte mobilization decreases patient

survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 19:

3404–3415. https://doi.org/10.1158/1078-0432.CCR-13-0525 Sangiolo D, Mesiano G, Gammaitoni L et al (2014) Cytokine-induced killer cells eradicate bone

and soft-tissue sarcomas. Cancer Res 74:119–129. https://doi.org/10.1158/0008-5472.CAN-

13-1559

Saxena M, van der Burg SH, Melief CJM, Bhardwaj N (2021) Therapeutic cancer vaccines. Nat

Rev Cancer 21:360–378. https://doi.org/10.1038/s41568-021-00346-0 Schäfer D, Tomiuk S, Küster LN et al (2021) Identiﬁcation of CD318, TSPAN8 and CD66c as

target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat

Commun 12:1453. https://doi.org/10.1038/s41467-021-21774-4 Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IGH (2015) Cytokine-induced killer (CIK) cells

in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res

Clin Oncol 141:839–849. https://doi.org/10.1007/s00432-014-1864-3 Schmidt-Wolf IG, Negrin RS, Kiem HP et al (1991) Use of a SCID mouse/human lymphoma model

to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:

139–149. https://doi.org/10.1084/jem.174.1.139 Schmitz-Winnenthal FH, Hohmann N, Niethammer AG et al (2015) Anti-angiogenic activity of

VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic

cancer: a randomized, placebo-controlled, phase 1 trial. Oncoimmunology 4:e1001217. https://

doi.org/10.1080/2162402X.2014.1001217

Seaman S, Zhu Z, Saha S et al (2017) Eradication of tumors through simultaneous ablation of

CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell 31:501–515.e8. https://

doi.org/10.1016/j.ccell.2017.03.005

Seifert L, Plesca I, Müller L et al (2021) LAG-3-expressing tumor-inﬁltrating T cells are associated

with reduced disease-free survival in pancreatic cancer. Cancers (Basel) 13. https://doi.org/10.

3390/cancers13061297

Sfanos KS, Bruno TC, Meeker AK et al (2009) Human prostate-inﬁltrating CD8+ T lymphocytes

are oligoclonal and PD-1+. Prostate 69:1694–1703. https://doi.org/10.1002/pros.21020 Shafer P, Kelly LM, Hoyos V (2022) Cancer therapy with TCR-engineered T cells: current

strategies, challenges, and prospects. Front Immunol 13. https://doi.org/10.3389/ﬁmmu.2022.

835762

Shen M, Hu P, Donskov F et al (2014) Tumor-associated neutrophils as a new prognostic factor in

cancer: a systematic review and meta-analysis. PLoS One 9:e98259. https://doi.org/10.1371/

journal.pone.0098259

Sherman MH, Yu RT, Engle DD et al (2014) Vitamin D receptor-mediated stromal reprogramming

suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80–93. https://doi.org/

10.1016/j.cell.2014.08.007

Sideras K, Braat H, Kwekkeboom J et al (2014) Role of the immune system in pancreatic cancer

progression and immune modulating treatment strategies. Cancer Treat Rev 40:513–522.

https://doi.org/10.1016/j.ctrv.2013.11.005

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:

17–48. https://doi.org/10.3322/caac.21763 Sinha P, Clements VK, Bunt SK et al (2007) Cross-talk between myeloid-derived suppressor cells

and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179:977–983.

https://doi.org/10.4049/jimmunol.179.2.977

Siret C, Collignon A, Silvy F et al (2020) Deciphering the crosstalk between myeloid-derived

suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front Immunol 10.

https://doi.org/10.3389/ﬁmmu.2019.03070

Soares KC, Rucki AA, Wu AA et al (2015) PD-1/PD-L1 blockade together with vaccine therapy

facilitates effector T-cell inﬁltration into pancreatic tumors. J Immunother 38:1–11. https://doi.

org/10.1097/CJI.0000000000000062

378 P. Farhangnia et al.

https://t.me/med1917

Sockolosky JT, Dougan M, Ingram JR et al (2016) Durable antitumor responses to CD47 blockade

require adaptive immune stimulation. Proc Natl Acad Sci 113:E2646–E2654. https://doi.org/10.

1073/pnas.1604268113

Stanietsky N, Simic H, Arapov ic J et al (2009) The interaction of TIGIT with PVR and PVRL2

inhibits human NK cell cytotoxicity. Proc Natl Acad Sci 106:17858 LP – 17863. https://doi.org/

10.1073/pnas.0903474106

Steele CW, Karim SA, Leach JDG et al (2016) CXCR2 inhibition profoundly suppresses metastases

and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29:832–845.

https://doi.org/10.1016/j.ccell.2016.04.014

Steele NG, Bifﬁ G, Kemp SB et al (2021) Inhibition of hedgehog signaling alters ﬁ broblast

composition in pancreatic cancer. Clin Cancer Res 27:2023–2037. https://doi.org/10.1158/

1078-0432.CCR-20-3715

Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies.

Blood Cancer J 11:69. https://doi.org/10.1038/s41408-021-00459-7 Stromnes IM, Brockenbrough JS, Izeradjene K et al (2014) Targeted depletion of an MDSC subset

unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769–1781. https://

doi.org/10.1136/gutjnl-2013-306271

Stromnes IM, Hulbert A, Pierce RH et al (2017) T-cell localization, activation, and clonal expansion

in human pancreatic ductal adenocarcinoma. Cancer Immunol Res 5:978–991. https://doi.org/

10.1158/2326-6066.CIR-16-0322

Takayama T, Sekine T, Makuuchi M et al (2000) Adoptive immunotherapy to lower postsurgical

recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807. https://

doi.org/10.1016/S0140-6736(00)02654-4

Tang R, Acharya N, Subramanian A et al (2023) Tim-3 adapter protein Bat3 acts as an endogenous

regulator of tolerogenic dendritic cell function. Sci Immunol 7:eabm0631. https://doi.org/10.

1126/sciimmunol.abm0631

Tao L, Zhang L, Peng Y et al (2016) Neutrophils assist the metastasis of circulating tumor cells in

pancreatic ductal adenocarcinoma: a new hypothesis and a new predictor for distant metastasis.

Medicine (Baltimore) 95:e4932. https://doi.org/10.1097/MD.0000000000004932 Tassi E, Gavazzi F, Albarello L et al (2008) Carcinoembryonic antigen-speciﬁc but not antiviral

CD4+ T cell immunity is impaired in pancreatic carcinoma patients1. J Immunol 181:

6595–6603. https://doi.org/10.4049/jimmunol.181.9.6595 Tekkesin N, Tetik S (2019) Chapter 14 – Therapeutic vaccines for pancreatic cancer. In: Nagaraju

GP, Ahmad SBT-TA, PC (eds) . Academic Press, London, pp 275–294 Teng K-Y, Mansour AG, Zhu Z et al (2022) Off-the-shelf prostate stem cell antigen–directed

chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer. Gastroenterology

162:1319–1333. https://doi.org/10.1053/j.gastro.2021.12.281 Timmer FEF, Geboers B, Nieuwenhuizen S et al (2021) Pancreatic cancer and immunotherapy: a

clinical overview. Cancers (Basel) 13. https://doi.org/10.3390/cancers13164138 Toda M, Martuza RL, Rabkin SD (2000) Tumor growth inhibition by intratumoral inoculation of

defective herpes simplex virus vectors expressing granulocyte–macrophage colony-stimulating

factor. Mol Ther 2:324–329. https://doi.org/10.1006/mthe.2000.0130 Tomar S, Zhang J, Khanal M et al (2022) Development of highly effective anti-mesothelin hYP218

chimeric antigen receptor T cells with increased tumor inﬁltration and persistence for treating

solid tumors. Mol Cancer Ther 21:1195–1206. https://doi.org/10.1158/1535-7163.MCT-

22-0073

Twyman-Saint Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade

activate non-redundant immune mechanisms in cancer. Nature 520:373–377. https://doi.org/10.

1038/nature14292

Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of

increasing myeloid cell diversity. Nat Rev Immunol 21:485–498. https://doi.org/10.1038/

s41577-020-00490-y

<<< < Предыдущая 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 3738 / 4138 39 40 41 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
10.10.20269 Мб0Книга_1501_Библиотеки_им_академика_М_И_Перельмана.djvu
#
10.10.20269 Мб0Книга_1505_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1506_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1507_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1509_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202610 Мб0Книга_151_библиотеки_им_акад_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1511_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1512_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1513_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_1514_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20268 Мб0Книга_1515_Библиотеки_им_академика_М_И_Перельмана.pdf